Print this page
-
Pilot Study of Renal Neoplasms with Perfusion Magnetic Resonance Imaging
Protocol: 081407Principal Investigator:
- Eric Singer M.D (Rutgers University)
Applicable Disease Sites: Kidney -
Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy in Patients with Lymphoma or Solid Tumor Malignancies
Protocol: 051901Principal Investigator:
- Jyoti Malhotra MD, MPH (Rutgers University)
Applicable Disease Sites: Non-Hodgkin's Lymphoma
Prostate
Pancreas
Kidney
Any Site
Hodgkin's Lymphoma -
Cyto-KIK; TRIAL (CYTO reductive surgery in Kidney cancer plus Immunotherapy (nivolumab) and targeted Kinase inhibition (cabozantinib).
Protocol: 082002Principal Investigator:
- Eric Singer M.D (Rutgers University)
Applicable Disease Sites: Kidney -
Phase 2 Trial of Voyager V1 (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination with Cemiplimab in patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial Carcinoma
Protocol: 052010Principal Investigator:
- Jyoti Malhotra MD, MPH (Rutgers University)
Applicable Disease Sites: Melanoma, Skin
Cervix
Lung
Liver
Kidney -
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy
Protocol: 082005Principal Investigator:
- Eric Singer M.D (Rutgers University)
Applicable Disease Sites: Kidney -
EA8143: A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Protocol: 081610Principal Investigator:
- Eric Singer M.D (Rutgers University)
Applicable Disease Sites: Kidney
- 1
- 2
